Nanoparticle–allergen complexes for allergen immunotherapy

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines.

Original languageEnglish
Pages (from-to)4493-4504
Number of pages12
JournalInternational Journal of Nanomedicine
Volume12
DOIs
Publication statusPublished - Jun 19 2017

Fingerprint

Allergens
Immunologic Desensitization
Nanoparticles
Allergies
Hypersensitivity
Costs and Cost Analysis
Vaccines
Immune system
Patient Compliance
Biological Availability
Costs
Immune System
Cells
Safety
Therapeutics
Population

Keywords

  • Allergens
  • Allergy
  • Immune modulation
  • Immunotherapy
  • Immunotoxicity
  • Nanocarriers

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Drug Discovery
  • Organic Chemistry

Cite this

Nanoparticle–allergen complexes for allergen immunotherapy. / Di Felice, Gabriella; Colombo, Paolo.

In: International Journal of Nanomedicine, Vol. 12, 19.06.2017, p. 4493-4504.

Research output: Contribution to journalReview article

@article{8d7c3a2580f64401990a6fad8560b7c1,
title = "Nanoparticle–allergen complexes for allergen immunotherapy",
abstract = "Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines.",
keywords = "Allergens, Allergy, Immune modulation, Immunotherapy, Immunotoxicity, Nanocarriers",
author = "{Di Felice}, Gabriella and Paolo Colombo",
year = "2017",
month = "6",
day = "19",
doi = "10.2147/IJN.S134630",
language = "English",
volume = "12",
pages = "4493--4504",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Nanoparticle–allergen complexes for allergen immunotherapy

AU - Di Felice, Gabriella

AU - Colombo, Paolo

PY - 2017/6/19

Y1 - 2017/6/19

N2 - Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines.

AB - Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines.

KW - Allergens

KW - Allergy

KW - Immune modulation

KW - Immunotherapy

KW - Immunotoxicity

KW - Nanocarriers

UR - http://www.scopus.com/inward/record.url?scp=85021104915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021104915&partnerID=8YFLogxK

U2 - 10.2147/IJN.S134630

DO - 10.2147/IJN.S134630

M3 - Review article

VL - 12

SP - 4493

EP - 4504

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -